Biogen Signals $34 Million Deal-Related Charge as It Reshapes Earnings Strategy

Biogen Inc. informed investors on Monday that it expects to record a $34 million charge in the first quarter related to licensing and research deals, which will reduce earnings per share by about 19 cents. This expense highlights the increasing cost associated with the company’s deal-driven growth strategy.

In a brief Securities and Exchange Commission filing, Biogen, based in Cambridge, Massachusetts, stated its GAAP and non-GAAP results for the quarter ended March 31 will include "acquired in-process research and development, upfront and milestone expense of approximately $34 million on a pre-tax basis."

The charge will reduce net income per diluted share for the quarter by about $0.19 on both GAAP and non-GAAP bases. The figures are preliminary as the quarter’s financial statements have not been finalized and remain subject to standard closing procedures.

A Small Filing, Big Implications

The charge is classified under Biogen’s "acquired in-process research and development, upfront and milestone expense" category, a line item introduced in early 2025 to separately report costs related to entering collaborations and licensing deals or acquiring early-stage assets. This category includes upfront payments, milestone payments, and premiums paid when applicable, expensed until regulatory approval is achieved.

Biogen has cautioned that such expenses are difficult to forecast due to their timing and size variability, and it excludes these charges from its annual earnings outlook. Nonetheless, it has issued multiple warnings in the past when these expenses have materially affected quarterly results.

Recent Deal Activity Linked to the Charge

While Biogen did not specify which deals contributed to the $34 million charge, recent transactions provide clues. In late March, Biogen signed an exclusive license agreement with South Korean biotech Alteogen Inc. for the rights to use ALT-B4 technology to develop subcutaneous versions of two Biogen biologic drugs. The deal includes a $20 million upfront payment plus possible milestone payments and royalties, making it a likely contributor to the recent charge.

Other collaborations, such as those with MorphoSys AG and City Therapeutics, also include milestone obligations that can trigger expenses when clinical or regulatory objectives are met.

Strategic Shift Amid Changing Revenue

Biogen is shifting focus away from its established multiple sclerosis (MS) drugs toward a diversified portfolio enriched by acquisitions and licensing deals. Sales of its MS drugs have fallen sharply due to generic competition and newer treatments, while newer products like the Alzheimer’s drug Leqembi and others have grown.

For 2026, Biogen expects a mid-single-digit revenue decline compared with 2025 and non-GAAP earnings per share roughly flat with last year. However, this guidance excludes the acquired in-process research and development expenses.

Since 2023, Biogen has made several acquisitions to bolster its pipeline, including the $6.5 billion Reata Pharmaceuticals acquisition, the $1.6 billion Human Immunology Biosciences purchase, and the planned $5.6 billion acquisition of Apellis Pharmaceuticals announced at the end of March. These deals are expected to boost earnings starting in 2027.

Impact on Patients and Pricing Considerations

Biogen’s licensing deals, such as the one with Alteogen, could improve patient convenience by enabling subcutaneous drug administration rather than lengthy infusions. However, such changes raise questions about pricing and out-of-pocket costs for patients, as well as implications for healthcare providers’ revenue models.

The acquisitions also involve treatments for rare diseases that often carry high price tags, intensifying scrutiny from regulatory authorities on drug costs and pricing strategies.

Legal and Disclosure Context

Biogen’s disclosures occur within a complex legal framework, following a $900 million settlement over allegations of illegal kickbacks and ongoing litigation related to its Alzheimer’s drugs.

The company’s practice of issuing separate regulatory filings to flag significant acquired in-process research and development expenses demonstrates an effort to provide transparent, real-time disclosure to investors. It underscores the risks and uncertainties inherent in such forward-looking statements.

Market Reaction and Outlook

Biogen’s stock dropped about 3% in early trading following the charge disclosure, reflecting investor concerns over deal-related earnings volatility.

Analysts generally support Biogen’s diversification strategy but caution that frequent acquisitions increase earnings volatility and complicate year-to-year financial comparisons.

Investors will look to Biogen’s full Q1 2026 earnings report later in April for finalized expense figures, updated guidance reflecting the Apellis acquisition, and further insights into newer product performance.

As Biogen continues reshaping its portfolio through acquisitions and partnerships, investors should anticipate ongoing impact from acquisition-related expenses on the company’s financial results.